Markt Patrick, Schuster Daniela, Kirchmair Johannes, Laggner Christian, Langer Thierry
Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innrain 52c, 6020 Innsbruck, Austria.
J Comput Aided Mol Des. 2007 Oct-Nov;21(10-11):575-90. doi: 10.1007/s10822-007-9140-0. Epub 2007 Oct 25.
We describe the generation and validation of pharmacophore models for PPARs, as well as a large scale validation of the parallel screening approach by screening PPAR ligands against a large database of structure-based models. A large test set of 357 PPAR ligands was screened against 48 PPAR models to determine the best models for agonists of PPAR-alpha, PPAR-delta, and PPAR-gamma. Afterwards, a parallel screen was performed using the 357 PPAR ligands and 47 structure-based models for PPARs, which were integrated into a 1537 models comprising in-house pharmacophore database, to assess the enrichment of PPAR ligands within the PPAR hypotheses. For these purposes, we categorized the 1537 database models into 181 protein targets and developed a score that ranks the retrieved targets for each ligand. Thus, we tried to find out if the concept of parallel screening is able to predict the correct pharmacological target for a set of compounds. The PPAR target was ranked first more often than any other target. This confirms the ability of parallel screening to forecast the pharmacological active target for a set of compounds.
我们描述了过氧化物酶体增殖物激活受体(PPARs)药效团模型的生成与验证,以及通过针对大量基于结构的模型筛选PPAR配体对平行筛选方法进行的大规模验证。针对48个PPAR模型筛选了包含357种PPAR配体的大型测试集,以确定针对PPAR-α、PPAR-δ和PPAR-γ激动剂的最佳模型。之后,使用357种PPAR配体和47个基于结构的PPAR模型进行平行筛选,这些模型被整合到一个包含内部药效团数据库的1537个模型中,以评估PPAR假设中PPAR配体的富集情况。为此,我们将1537个数据库模型分类为181个蛋白质靶点,并开发了一个对每个配体检索到的靶点进行排名的分数。因此,我们试图弄清楚平行筛选的概念是否能够预测一组化合物的正确药理靶点。PPAR靶点比其他任何靶点更常排名第一。这证实了平行筛选预测一组化合物药理活性靶点的能力。